abbvie glp-1 plans to build out its presence in obesity market AbbVie shares early weight-loss data

Retrieved 14 May 2022, from A Phase III, Multicentre, Double-Blind, Randomized, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients with Erythropoietic Protoporphyria (EPP)

That does not mean the product page should make endpoint claims

Backed by extensive scientific evidence from rigorous clinical trials and corroborated by real-world data showing substantial, sustained fat mass reduction, metabolic improvements, and enhanced quality of life, it serves as a powerful, medically supervised tool

Introduction and Background GLP-1 (Glucagon-Like Peptide-1) is a hormone that has gone from a physiological curiosity to a therapeutic powerhouse in recent decades

Hundley IT Consultant Danny J